KZIA Stock News Today: Kazia Therapeutics Soars on Rare Cancer Response as Nasdaq Delisting Risk Looms
Kazia Therapeutics reported a rare immune-complete response in a stage IV triple-negative breast cancer patient treated with paxalisib, Keytruda, and chemotherapy. Shares surged over 50% after hours, but the company also disclosed a fresh Nasdaq delisting warning and filed a new prospectus supplement. Kazia plans to request a hearing to contest the delisting.
